Literature DB >> 33469123

Optimal combination treatment regimens of vaccine and radiotherapy augment tumor-bearing host immunity.

Fayun Zhang1, Zifeng Zheng2,3, Apurba Kumar Barman4, Zihao Wang2, Luyao Wang2, Wenfeng Zeng2, Luoyang Wang5, Yan Qin2, Asmita Pandey2, Chunling Zhang2, Wei Liang6,7.   

Abstract

A major obstacle to immunotherapy is insufficient infiltration of effector immune cells into the tumor microenvironment. Radiotherapy greatly reduces tumor burden but relapses often occur. Here we show that the immunosuppressive tumor microenvironment was gradually established by recruiting Tregs after radiation. Despite tumors being controlled after depletion of Tregs in the irradiated area, improvement of mice survival remained poor. A much better antitumor effect was achieved with vaccination followed by radiation than other treatments. Vaccination followed by radiation recruited more effector T cells in tumor regions, which responded to high levels of chemokines. Sequential combination of vaccination and radiotherapy could elicit distinct host immune responses. Our study demonstrated that optimal combination of irradiation and vaccination is required to achieve effective antitumor immune responses. We propose a combination regimen that could be easily translated into the clinic and offer an opportunity for rational combination therapies design in cancer treatment.

Entities:  

Year:  2021        PMID: 33469123      PMCID: PMC7815836          DOI: 10.1038/s42003-020-01598-6

Source DB:  PubMed          Journal:  Commun Biol        ISSN: 2399-3642


  55 in total

Review 1.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self.

Authors:  Shimon Sakaguchi
Journal:  Nat Immunol       Date:  2005-04       Impact factor: 25.606

Review 2.  Unravelling the nature of non-specific effects of vaccines-A challenge for innate immunologists.

Authors:  Kristoffer Jarlov Jensen; Christine Stabell Benn; Reinout van Crevel
Journal:  Semin Immunol       Date:  2016-06-25       Impact factor: 11.130

3.  Tumor-infiltrating CD45RO(+) memory cells are associated with a favorable prognosis breast cancer.

Authors:  Reina Yajima; Toshiki Yajima; Takaaki Fujii; Yasuhiro Yanagita; Tomomi Fujisawa; Takeshi Miyamoto; Soichi Tsutsumi; Misa Iijima; Hiroyuki Kuwano
Journal:  Breast Cancer       Date:  2015-06-14       Impact factor: 4.239

Review 4.  The immune contexture in human tumours: impact on clinical outcome.

Authors:  Wolf Herman Fridman; Franck Pagès; Catherine Sautès-Fridman; Jérôme Galon
Journal:  Nat Rev Cancer       Date:  2012-03-15       Impact factor: 60.716

5.  Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade.

Authors:  Haidong Tang; Yang Wang; Lukasz K Chlewicki; Yuan Zhang; Jingya Guo; Wei Liang; Jieyi Wang; Xiaoxiao Wang; Yang-Xin Fu
Journal:  Cancer Cell       Date:  2016-03-14       Impact factor: 31.743

6.  The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies.

Authors:  Junko Ozao-Choy; Ge Ma; Johnny Kao; George X Wang; Marcia Meseck; Max Sung; Myron Schwartz; Celia M Divino; Ping-Ying Pan; Shu-Hsia Chen
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

7.  A Prospective Clinical Trial Combining Radiation Therapy With Systemic Immunotherapy in Metastatic Melanoma.

Authors:  Susan M Hiniker; Sunil A Reddy; Holden T Maecker; Priyanka B Subrahmanyam; Yael Rosenberg-Hasson; Susan M Swetter; Saurabh Saha; Lei Shura; Susan J Knox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-07-15       Impact factor: 7.038

8.  Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.

Authors:  Ayman Oweida; Mohammad K Hararah; Andy Phan; David Binder; Shilpa Bhatia; Shelby Lennon; Sanjana Bukkapatnam; Benjamin Van Court; Nomin Uyanga; Laurel Darragh; Hyun Min Kim; David Raben; Aik Choon Tan; Lynn Heasley; Eric Clambey; Raphael Nemenoff; Sana D Karam
Journal:  Clin Cancer Res       Date:  2018-07-24       Impact factor: 12.531

9.  A systematic analysis of experimental immunotherapies on tumors differing in size and duration of growth.

Authors:  Frank T Wen; Ronald A Thisted; Donald A Rowley; Hans Schreiber
Journal:  Oncoimmunology       Date:  2012-03-01       Impact factor: 8.110

10.  An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer.

Authors:  Marian L Burr; Christina E Sparbier; Kah Lok Chan; Yih-Chih Chan; Ariena Kersbergen; Enid Y N Lam; Elizabeth Azidis-Yates; Dane Vassiliadis; Charles C Bell; Omer Gilan; Susan Jackson; Lavinia Tan; Stephen Q Wong; Sebastian Hollizeck; Ewa M Michalak; Hannah V Siddle; Michael T McCabe; Rab K Prinjha; Glen R Guerra; Benjamin J Solomon; Shahneen Sandhu; Sarah-Jane Dawson; Paul A Beavis; Richard W Tothill; Carleen Cullinane; Paul J Lehner; Kate D Sutherland; Mark A Dawson
Journal:  Cancer Cell       Date:  2019-09-26       Impact factor: 31.743

View more
  1 in total

1.  Tumor cell-based vaccine contributes to local tumor irradiation by eliciting a tumor model-dependent systemic immune response.

Authors:  Tinkara Remic; Gregor Sersa; Kristina Levpuscek; Ursa Lampreht Tratar; Katja Ursic Valentinuzzi; Andrej Cör; Urska Kamensek
Journal:  Front Immunol       Date:  2022-09-05       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.